Journal of Neuro-Oncology

, Volume 90, Issue 2, pp 201–204 | Cite as

Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma

  • Alyx B. Porter
  • Dirk M. Bernold
  • Caterina Giannini
  • Robert L. Foote
  • Michael J. Link
  • Kerry D. Olsen
  • Timothy J. Moynihan
  • Jan C. Buckner
Clinical Study - Patient Study


Background Esthesioneuroblastoma (ENB) is a rare tumor arising from the olfactory epithelium in the upper nasal cavity. Prior reviews have found efficacy of chemotherapy for high grade tumors in the advanced setting. However, little information is available regarding chemotherapy in the adjuvant setting. Methods A retrospective review of 76 patients treated at the Mayo Clinic for esthesioneuroblastoma from 1976 to 2003 was performed to evaluate adjuvant chemotherapy (AC) in these patients. Pathology slides were reviewed to assign Hyam’s grade, and modified Kadish staging was available for all patients used in the analysis. Results Twelve patients were identified to have had full surgical resection of Stage C, high grade (grade 3 or 4) tumors. Six of these patients received AC, and six did not. Most AC was cisplatin and etoposide based. Median time to relapse for patients who did and did not receive AC is 35 and 10.5 months respectively. The median overall survival (OS) for patients that received AC was 83+ (range 21–119+ months). The median OS for patients not receiving AC is 78 months (range 9–240+ months). Conclusions This small retrospective series suggests that adjuvant therapy for patients with high grade, Stage C esthesioneuroblastoma is of benefit following complete resection. Radiation therapy alone provides an improvement in time to relapse, which may be increased further with the addition of cisplatin and etoposide based chemotherapy.


Esthesioneuroblastoma Radiation Adjuvant chemotherapy 


  1. 1.
    Morita A, Ebersold MJ, Olsen KD et al (1993) Esthesioneuroblastoma: prognosis and management. Neurosurgery 32:706–715PubMedCrossRefGoogle Scholar
  2. 2.
    Dulguerov P, Allal AS, Calcaterra TC (2001) Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2:683. doi: 10.1016/S1470-2045(01)00558-7 PubMedCrossRefGoogle Scholar
  3. 3.
    Kim DW, Jo YH, Kim JH, Wu HG, Rhee CS, Lee CH et al (2004) Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 101(10):2257–2260. doi: 10.1002/cncr.20648 PubMedCrossRefGoogle Scholar
  4. 4.
    Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA et al (2006) Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg 132(2):134–138. doi: 10.1001/archotol.132.2.134 PubMedCrossRefGoogle Scholar
  5. 5.
    McElroy EA, Buckner JC, Lewis JE (1998) Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 42:1023. doi: 10.1097/00006123-199805000-00040 PubMedCrossRefGoogle Scholar
  6. 6.
    Kadish S, Goodman M, Wang CC (1976) Olfactory neuroblastoma: a clinical analysis on 17 cases. Cancer 37:1571–1576. doi:10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-LPubMedCrossRefGoogle Scholar
  7. 7.
    Boni C, Cocconi G, Bisagni G, Ceci G, Perrachia G (1989) Cisplatin and etoposide (VP16) as a single cell regimen for the treatment of small cell lung cancer: a Phase II trial. Cancer 63:638–642. doi:10.1002/1097-0142(19890215)63:4<638::AID-CNCR2820630406>3.0.CO;2-8PubMedCrossRefGoogle Scholar
  8. 8.
    Hyams VJ, Batsakis JG, Michaels L (1988) Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington, pp 240–248Google Scholar
  9. 9.
    Chamberlain MC (2002) Treatment of intracranial metastatic esthesioneuroblastoma. J Clin Oncol 20:357–358PubMedGoogle Scholar
  10. 10.
    Wade PM, Smith RE, Johns ME (1984) Response of esthesioneuroblastoma to chemotherapy. Cancer 53:1036–1041. doi:10.1002/1097-0142(19840301)53:5<1036::AID-CNCR2820530504>3.0.CO;2-3PubMedCrossRefGoogle Scholar
  11. 11.
    Goldsweig HG, Sundaresan N (1990) Chemotherapy of recurrent esthesioneuroblastoma: case report and review of the literature. Am J Clin Oncol 13:139–143. doi: 10.1097/00000421-199004000-00010 PubMedCrossRefGoogle Scholar
  12. 12.
    Diaz E, Johnigan R, Pero C et al (2005) Olfactory neuroblastoma: the 22 year experience at one comprehensive cancer center. Head Neck (February):138–149. doi: 10.1002/hed.20127
  13. 13.
    McLean JN, Nunley S, Klass C, Moore C, Muller S, Johnstone P (2007) Combined modality therapy of esthesioneuroblastoma. Otolaryngol Head Neck Surg 136:998–1002. doi: 10.1016/j.otohns.2006.11.051 PubMedCrossRefGoogle Scholar
  14. 14.
    Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC (1997) Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined therapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg Fan 123(1):34–40Google Scholar
  15. 15.
    Fitznek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J et al (2002) Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer 94(10):2623–2634. doi: 10.1002/cncr.10537 CrossRefGoogle Scholar
  16. 16.
    Foote RL, Morita A, Eberssold MJ et al (1993) Esthesioneuroblastoma: the role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 27:835PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Alyx B. Porter
    • 1
  • Dirk M. Bernold
    • 2
  • Caterina Giannini
    • 3
  • Robert L. Foote
    • 4
  • Michael J. Link
    • 5
  • Kerry D. Olsen
    • 6
  • Timothy J. Moynihan
    • 2
  • Jan C. Buckner
    • 2
  1. 1.Department of NeurologyMayo ClinicRochesterUSA
  2. 2.Department of OncologyMayo ClinicRochesterUSA
  3. 3.Department of PathologyMayo ClinicRochesterUSA
  4. 4.Department of Radiation OncologyMayo ClinicRochesterUSA
  5. 5.Department of NeurosurgeryMayo ClinicRochesterUSA
  6. 6.Department of OtolaryngologyMayo ClinicRochesterUSA

Personalised recommendations